Pablo Ramos-García1, Miguel Ángel González-Moles2, Lucía González-Ruiz3, Isabel Ruiz-Ávila4, Ángela Ayén5, José Antonio Gil-Montoya6. 1. School of Dentistry, University of Granada, Granada, Spain. Electronic address: pramos@correo.ugr.es. 2. School of Dentistry, University of Granada, Granada, Spain; Instituto de Investigación Biosanitaria, Granada, Spain. Electronic address: magonzal@ugr.es. 3. Servicio de Dermatología, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain. 4. Instituto de Investigación Biosanitaria, Granada, Spain; Servicio de Anatomía Patológica, Complejo Hospitalario Universitario de Granada, Granada, Spain. 5. School of Medicine, University of Granada, Granada, Spain. 6. School of Dentistry, University of Granada, Granada, Spain; Instituto de Investigación Biosanitaria, Granada, Spain. Electronic address: jagil@ugr.es.
Abstract
OBJECTIVES: To evaluate the prognostic significance of cyclin D1 (CD1) overexpression in OSCC. MATERIAL AND METHODS: We searched studies published before August 2017 (Pubmed, Embase, Web of Science, Scopus). We evaluated the quality of the studies included (Quality in Prognosis Studies [QUIPS] tool). The impact of CD1 overexpression on overall survival and disease-free survival, T status, N status, stage, and histological degree was meta-analyzed. We analyzed heterogeneity among studies, conducted sensitivity analyses, analyzed small-study effects, and conducted subgroup analyses. RESULTS: 31 studies (2942 patients) met inclusion criteria. Qualitative evaluation demonstrated that not all studies were performed with the same rigor, finding the greatest risk of bias in the study confounding domain. Quantitative evaluation showed that CD1 overexpression had a strong statistical association with worse overall survival (HR = 2.00, 95% CI = 1.59-2.51, p < 0.001), worse disease-free survival (HR = 1.46, 95% CI = 1.13-1.87, p = 0.003), higher T status (OR = 1.51, 95% CI = 1.07-2.13, p = 0.02), N+ status (OR = 2.16, 95% CI = 1.60-2.92, p < 0.001), advanced stage (OR = 1.44, 95% CI = 1.15-1.81, p = 0.002), and high histological grade (OR = 1.60, 95% CI = 1.12-2.29, p = 0.010). We observed heterogeneity in all parameters except for disease-free survival and clinical stage. We found effect of small studies on T and N status. The tonguel SCC subgroup showed the strongest association between CD1 overexpression and worse development. In addition, application of a cutoff point ≥10% tumor cells with nuclear CD1 expression maintained most of the significant associations reported. CONCLUSIONS: These findings indicate that immunohistochemical assessment of CD1 overexpression may be useful as a prognostic biomarker for OSCC.
OBJECTIVES: To evaluate the prognostic significance of cyclin D1 (CD1) overexpression in OSCC. MATERIAL AND METHODS: We searched studies published before August 2017 (Pubmed, Embase, Web of Science, Scopus). We evaluated the quality of the studies included (Quality in Prognosis Studies [QUIPS] tool). The impact of CD1 overexpression on overall survival and disease-free survival, T status, N status, stage, and histological degree was meta-analyzed. We analyzed heterogeneity among studies, conducted sensitivity analyses, analyzed small-study effects, and conducted subgroup analyses. RESULTS: 31 studies (2942 patients) met inclusion criteria. Qualitative evaluation demonstrated that not all studies were performed with the same rigor, finding the greatest risk of bias in the study confounding domain. Quantitative evaluation showed that CD1 overexpression had a strong statistical association with worse overall survival (HR = 2.00, 95% CI = 1.59-2.51, p < 0.001), worse disease-free survival (HR = 1.46, 95% CI = 1.13-1.87, p = 0.003), higher T status (OR = 1.51, 95% CI = 1.07-2.13, p = 0.02), N+ status (OR = 2.16, 95% CI = 1.60-2.92, p < 0.001), advanced stage (OR = 1.44, 95% CI = 1.15-1.81, p = 0.002), and high histological grade (OR = 1.60, 95% CI = 1.12-2.29, p = 0.010). We observed heterogeneity in all parameters except for disease-free survival and clinical stage. We found effect of small studies on T and N status. The tonguel SCC subgroup showed the strongest association between CD1 overexpression and worse development. In addition, application of a cutoff point ≥10% tumor cells with nuclear CD1 expression maintained most of the significant associations reported. CONCLUSIONS: These findings indicate that immunohistochemical assessment of CD1 overexpression may be useful as a prognostic biomarker for OSCC.
Authors: Miguel Ángel González-Moles; Saman Warnakulasuriya; María López-Ansio; Pablo Ramos-García Journal: Cancers (Basel) Date: 2022-08-08 Impact factor: 6.575
Authors: Zuo-You Ding; Ran Li; Qi-Jie Zhang; Yi Wang; Yi Jiang; Qing-Yang Meng; Qiu-Lei Xi; Guo-Hao Wu Journal: Cancer Med Date: 2019-04-05 Impact factor: 4.452
Authors: Aaron Chen; Alexis L Santana; Nicole Doudican; Nazanin Roudiani; Kristian Laursen; Jean-Philippe Therrien; James Lee; Diane Felsen; John A Carucci Journal: PLoS One Date: 2020-11-23 Impact factor: 3.240